Quince Therapeutics, Inc.QNCX

Quince Therapeutics booked $35.9 million of net income in the quarter to March 31, according to its latest 10-Q, but the same filing shows $18.2 million of cash and $11 million of liabilities, which is the first place the polished platform story meets the plain balance sheet. The company’s AIDE technology platform is presented as a twenty-year, $100 million moat, complete with a sci-fi lab photo, while the cash position is closer to a start-up’s than a corporate R&D powerhouse. The gap matters because the company is still burning cash-operating losses were $14.6 million in the same quarter-so the net income looks like either a one-off accounting feature or a genuine inflection point worth watching.

What Quince actually does is develop eDSP, an intra-erythrocyte dexamethasone sodium phosphate, which the company says is intended to treat rare diseases where precise delivery of a payload can change outcomes. The official pipeline shows a pivotal Phase 3 NEAT trial in A-T patients, a rare neurodegenerative disease, and the team page lists Brigette Roberts, M.D., as Chief Medical Officer-credentials that sound impressive until you notice the company’s liabilities still exceed its assets by $11 million to $26.6 million, leaving shareholders with $15.7 million of equity. The science is serious; the capital math is less so.

The filings do not hide the tension. The 10-Q for the quarter ending March 31 lists net income of $35.9 million, operating loss of $14.6 million, R&D expense of $6.8 million, and weighted average diluted shares of 9.2 million, giving an EPS of $2.88. Cash used in operations was $7.6 million, and the company held no short-term investments. The balance sheet is simple: $26.6 million of assets, $11 million of liabilities, $15.7 million of shareholders’ equity, and $18.2 million of cash. Capital expenditure was zero, which either means the company is asset-light or that its heavy lifting happens elsewhere.

If you want a chart, the company’s SEC filings are the primary rail; TradingView’s QNCX chart is secondary and carries no source-backed facts beyond price and volume. The operating story is what matters here: cash, burn, and the gap between the platform narrative and the filed numbers. The tension is that the company’s lead asset is in a pivotal trial, but the balance sheet still looks like a pre-revenue biotech with a single shot on goal. The next catalyst will be the Phase 3 NEAT results and any update on the Orphai acquisition and the potential $187 million private placement.

The company’s 8-Ks in late June show a flurry of activity: an 8-K/A announcing the acquisition of Orphai and a potential $187 million private placement sits next to an 8-K updating insider share movements, and the same week’s Form 4 filings show directors and officers buying and selling. The optics are neat, but the filing math stays the same: $18.2 million in cash, $11 million in liabilities, and $6.8 million spent on R&D in three months. The market narrative loves a fundraise, but the balance sheet tells a different story. The company’s cash runway and the timing of any cash call will be the next pressure point.

The evidence does not show revenue, segment performance, or guidance, so the file cannot state whether the net income is recurring, one-off, or accounting-driven. The company’s pipeline includes eDSP for A-T and planned Phase 2 studies in DMD, but the filings do not disclose any sales, approvals, or customer agreements. The AIDE platform is described as a twenty-year, $100 million innovation, but the balance sheet shows no corresponding asset build; the $100 million figure appears only on the website, not in the 10-Q. The Phase 3 NEAT trial is pivotal, but the filing does not state whether the topline results are positive, negative, or pending. The Orphai acquisition and potential $187 million private placement are material developments, but the filings do not disclose terms, dilution, or use of proceeds. Until the company files a detailed 8-K on the fundraise or releases NEAT results, the file must treat the cash position and the science as the primary facts.